1. Home
  2. KYMR
  3. KYMR News

Latest Kymera Therapeutics Inc. (KYMR) News on March 29, 2025

KYMR

MT Newswires

16 days ago

Citigroup Initiates Coverage on Kymera Therapeutics With Buy Rating, $52 Price Target

Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook
KYMR

Simply Wall St.

23 days ago

Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates
KYMR

Simply Wall St.

a month ago

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
KYMR

Zacks

a month ago

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate
KYMR

Simply Wall St.

a month ago

We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate

Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...
KYMR

GuruFocus.com

a month ago

Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...

KYMR

MT Newswires

a month ago

Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
KYMR

Zacks

a month ago

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
KYMR

GlobeNewswire

a month ago

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

What To Expect From Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings
KYMR

GuruFocus.com

a month ago

What To Expect From Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings

Kymera Therapeutics to Participate in Upcoming March Investor Conferences
KYMR

GlobeNewswire

a month ago

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27
KYMR

GlobeNewswire

a month ago

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

NAYA Biosciences Announces Nomination of New Board Members
KYMR

GlobeNewswire

a month ago

NAYA Biosciences Announces Nomination of New Board Members

Kymera Therapeutics to Participate in Upcoming February Investor Conferences
KYMR

GlobeNewswire

2 months ago

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Kymera Provides Pipeline Objectives for 2025, Stock Gains
KYMR

Zacks

2 months ago

Kymera Provides Pipeline Objectives for 2025, Stock Gains

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?
KYMR

Zacks

2 months ago

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments
KYMR

GuruFocus.com

2 months ago

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
KYMR

GlobeNewswire

2 months ago

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
KYMR

GlobeNewswire

3 months ago

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal
KYMR

TipRanks

3 months ago

Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal

KYMR

MT Newswires

4 months ago

BMO Capital Initiates Kymera Therapeutics at Market Perform With $55 Price Target

KYMR

MT Newswires

4 months ago

Kymera Therapeutics Shares Rise After Upgrade From Wells Fargo

KYMR

MT Newswires

4 months ago

Wells Fargo Upgrades Kymera Therapeutics to Overweight, Price Target is $57

Kymera Therapeutics to Participate in Upcoming December Investor Conferences
KYMR

GlobeNewswire

4 months ago

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

Kymera Therapeutics to Participate in Upcoming November Investor Conferences
KYMR

GlobeNewswire

5 months ago

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

KYMR

MT Newswires

5 months ago

UBS Adjusts Price Target on Kymera Therapeutics to $74 From $80, Maintains Buy Rating

Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report
KYMR

Simply Wall St.

5 months ago

Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report

Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
KYMR

Simply Wall St.

5 months ago

Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
KYMR

Zacks

5 months ago

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus

KYMR

MT Newswires

5 months ago

B. Riley Adjusts Price Target on Kymera Therapeutics to $41 From $36, Maintains Neutral Rating

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
KYMR

GuruFocus.com

5 months ago

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners
KYMR

The Wall Street Journal

5 months ago

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners

KYMR

MT Newswires

5 months ago

Truist Trims Price Target on Kymera Therapeutics to $53 From $54, Keeps Buy Rating

KYMR

MT Newswires

5 months ago

Kymera Therapeutics Shares Fall After Q3 Loss, Lower Revenue

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates
KYMR

Zacks

5 months ago

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
KYMR

GlobeNewswire

5 months ago

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of Earnings
KYMR

GuruFocus.com

5 months ago

Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of Earnings

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
KYMR

Zacks

5 months ago

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
KYMR

Zacks

5 months ago

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
KYMR

GlobeNewswire

5 months ago

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
KYMR

GlobeNewswire

5 months ago

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
KYMR

GlobeNewswire

5 months ago

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
KYMR

Zacks

6 months ago

Kymera's IND Application for STAT6 Degrader Gets FDA Clearance

KYMR

MT Newswires

6 months ago

Kymera Therapeutics Says US FDA Clears Investigational New Drug Application for KT-621

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
KYMR

GlobeNewswire

6 months ago

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

KYMR

MT Newswires

6 months ago

Oppenheimer Adjusts Kymera Therapeutics Price Target to $56 From $52, Maintains Outperform Rating

KYMR

MT Newswires

6 months ago

Kymera Therapeutics Says its Potential IND KT-621 Reduced Inflammation in Preclinical Models

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
KYMR

GlobeNewswire

6 months ago

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
KYMR

Zacks

7 months ago

Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?

Kymera Therapeutics to Participate in Upcoming September Investor Conferences
KYMR

GlobeNewswire

7 months ago

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

KYMR

MT Newswires

7 months ago

Kymera Therapeutics Shares Rise After Wolfe Research Upgrade

KYMR

MT Newswires

7 months ago

Wolfe Research Upgrades Kymera Therapeutics to Outperform From Peer Perform

KYMR

MT Newswires

7 months ago

Kymera Therapeutics Closes Upsized $225 Million Public Offering

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
KYMR

GlobeNewswire

7 months ago

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Kymera (KYMR) to Raise $225 Million Through Offering of Shares
KYMR

Zacks

7 months ago

Kymera (KYMR) to Raise $225 Million Through Offering of Shares

Avidity, Kymera raise fresh funds; Walgreens partners with BARDA
KYMR

BioPharma Dive

7 months ago

Avidity, Kymera raise fresh funds; Walgreens partners with BARDA

KYMR

MT Newswires

7 months ago

Kymera Therapeutics Prices $225 Million Offering of Common Shares, Warrants

Kymera Therapeutics Announces Pricing of $225 Million Public Offering
KYMR

GlobeNewswire

7 months ago

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

KYMR

MT Newswires

7 months ago

Kymera Therapeutics Unveils $200 Million Public Offering -- Shares Slip After Hours

Kymera Therapeutics Announces Proposed Public Offering
KYMR

GlobeNewswire

7 months ago

Kymera Therapeutics Announces Proposed Public Offering

Earnings Beat: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
KYMR

Simply Wall St.

8 months ago

Earnings Beat: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus
KYMR

Zacks

8 months ago

Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus

Kymera Therapeutics Second Quarter 2024 Earnings: Beats Expectations
KYMR

Simply Wall St.

8 months ago

Kymera Therapeutics Second Quarter 2024 Earnings: Beats Expectations

KYMR

MT Newswires

8 months ago

Kymera Therapeutics Q2 Net Loss Narrows, Revenue Rises; Shares Fall Pre-Bell

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
KYMR

Zacks

8 months ago

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
KYMR

GlobeNewswire

8 months ago

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
KYMR

GlobeNewswire

8 months ago

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

We're Not Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn
KYMR

Simply Wall St.

8 months ago

We're Not Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
KYMR

Zacks

9 months ago

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?
KYMR

Zacks

9 months ago

Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?

Why Kymera Therapeutics Stock Is Soaring Today
KYMR

Motley Fool

9 months ago

Why Kymera Therapeutics Stock Is Soaring Today

KYMR

Investing.com

9 months ago

Kymera Therapeutics soars as Sanofi expands phase 2 trials

Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug
KYMR

Investopedia

9 months ago

Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
KYMR

Zacks

9 months ago

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies

KYMR

MT Newswires

9 months ago

B. Riley Adjusts Price Target on Kymera Therapeutics to $36 From $31, Maintains Neutral Rating

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
KYMR

GlobeNewswire

9 months ago

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

KYMR

MT Newswires

9 months ago

Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
KYMR

GlobeNewswire

9 months ago

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
KYMR

GlobeNewswire

9 months ago

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

FDA panel votes to recommend Eli Lilly's Alzheimer's drug
KYMR

Yahoo Finance Video

10 months ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

KYMR

GlobeNewswire

10 months ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit
KYMR

Reuters

10 months ago

California seeks company profits in Big Oil climate lawsuit

KYMR

USA TODAY

10 months ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
KYMR

GlobeNewswire

10 months ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
KYMR

Business Wire

10 months ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research
KYMR

GlobeNewswire

10 months ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas
KYMR

Business Wire

10 months ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
KYMR

GOBankingRates

10 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
KYMR

Business Insider

10 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women
KYMR

Insider Monkey

10 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase
KYMR

Reuters

10 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

KYMR

Insider Monkey

10 months ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow
KYMR

AFP

10 months ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events
KYMR

Investor's Business Daily

10 months ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

European Union Vote Delivers Shift to Right, in Blow to French and German Governments
KYMR

The Wall Street Journal

10 months ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
KYMR

GlobeNewswire

10 months ago

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Kymera Therapeutics to Participate in Upcoming June Investor Conferences
KYMR

GlobeNewswire

10 months ago

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
KYMR

GlobeNewswire

10 months ago

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
KYMR

GlobeNewswire

10 months ago

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
KYMR

GlobeNewswire

10 months ago

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Share on Social Networks: